Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec as Adjuvant Therapy in High-Risk GIST
NCT00171977Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Relapse-Free Survival at 3 years. Started Jul 2004; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00171977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171977.